Dicarboxylic acid dipeptide neutral endopeptidase inhibitors

Area of Science:

• Medicinal Chemistry
• Pharmacology
• Biochemistry

Background:

• Neutral endopeptidase 24.11 (NEP) is a key enzyme in regulating blood pressure and fluid balance.
• Developing potent and selective NEP inhibitors is a therapeutic target for cardiovascular diseases.

Purpose of the Study:

• To synthesize and characterize novel dicarboxylic acid dipeptide NEP inhibitors.
• To evaluate the in vitro and in vivo efficacy of these inhibitors, focusing on compound 21a.

Main Methods:

• Synthesis of three series of dicarboxylic acid dipeptide derivatives.
• In vitro enzyme inhibition assays to determine IC50 values.
• In vivo studies in rats and dogs to assess pharmacokinetic properties and physiological effects.
• High-performance liquid chromatography (HPLC) for drug concentration measurements.

Main Results:

• Compound 21a exhibited potent NEP inhibitory activity with an IC50 of 5.0 nM.
• Ex vivo analysis confirmed sustained high free drug concentrations (10-1500 times greater than Ki) for 6 hours.
• Oral administration of compound 19a elevated plasma atrial natriuretic factor levels in rats and dogs.
• Compound 21a potentiated urinary volume and sodium excretion in anesthetized dogs.

Conclusions:

• Dicarboxylic acid dipeptide derivatives represent a promising class of NEP inhibitors.
• Compound 21a demonstrates significant in vitro and in vivo NEP inhibitory activity and favorable pharmacokinetic profiles.
• These findings suggest potential therapeutic applications for NEP inhibitors in managing conditions related to fluid and electrolyte balance.